TESLAC Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Teslac, and what generic alternatives are available?
Teslac is a drug marketed by Bristol Myers Squibb and is included in two NDAs.
The generic ingredient in TESLAC is testolactone. There are two drug master file entries for this compound. Additional details are available on the testolactone profile page.
Summary for TESLAC
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 31 |
Clinical Trials: | 1 |
Patent Applications: | 7,037 |
Formulation / Manufacturing: | see details |
DailyMed Link: | TESLAC at DailyMed |
Recent Clinical Trials for TESLAC
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Phase 2 |
US Patents and Regulatory Information for TESLAC
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bristol Myers Squibb | TESLAC | testolactone | INJECTABLE;INJECTION | 016119-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Bristol Myers Squibb | TESLAC | testolactone | TABLET;ORAL | 016118-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Bristol Myers Squibb | TESLAC | testolactone | TABLET;ORAL | 016118-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |